BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17920351)

  • 1. 3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors.
    Seibyl JP; Chen W; Silverman DH
    Semin Nucl Med; 2007 Nov; 37(6):440-50. PubMed ID: 17920351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
    Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
    J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical utility of (18)F-DOPA-PET in movement disorders. A systematic review].
    Puñal-Riobóo J; Serena-Puig A; Varela-Lema L; Alvarez-Páez AM; Ruano-Ravina A
    Rev Esp Med Nucl; 2009; 28(3):106-13. PubMed ID: 19558950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dual time point 18F-FDOPA PET as a tool for characterizing brain tumors].
    González-Forero M; Prieto E; Domínguez I; Vigil C; Peñuelas I; Arbizu J
    Rev Esp Med Nucl; 2011; 30(2):88-93. PubMed ID: 21334774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
    Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M
    PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders.
    Stormezand GN; Chaves LT; Vállez García D; Doorduin J; De Jong BM; Leenders KL; Kremer BPH; Dierckx RAJO
    Neuroimage Clin; 2020; 25():102161. PubMed ID: 31981888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and grading accuracy of
    Xiao J; Jin Y; Nie J; Chen F; Ma X
    BMC Cancer; 2019 Aug; 19(1):767. PubMed ID: 31382920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
    Santhanam P; Taïeb D
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high
    Isal S; Gauchotte G; Rech F; Blonski M; Planel S; Chawki MB; Karcher G; Marie PY; Taillandier L; Verger A
    Br J Radiol; 2018 Apr; 91(1084):20170803. PubMed ID: 29271237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
    Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
    J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study.
    Kuten J; Linevitz A; Lerman H; Freedman N; Kestenbaum M; Shiner T; Giladi N; Even-Sapir E
    J Integr Neurosci; 2020 Sep; 19(3):489-494. PubMed ID: 33070528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study.
    Ma Y; Feigin A; Dhawan V; Fukuda M; Shi Q; Greene P; Breeze R; Fahn S; Freed C; Eidelberg D
    Ann Neurol; 2002 Nov; 52(5):628-34. PubMed ID: 12402261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F-FDOPA accumulation in traumatic rib fractures: a potential pitfall.
    Stormezand GN; Glaudemans AW; Slart RH
    Clin Nucl Med; 2015 Jun; 40(6):531-2. PubMed ID: 25742233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
    Wardak M; Schiepers C; Cloughesy TF; Dahlbom M; Phelps ME; Huang SC
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1199-209. PubMed ID: 24604590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDOPA PET for the diagnosis of parkinsonian syndromes.
    Darcourt J; Schiazza A; Sapin N; Dufour M; Ouvrier MJ; Benisvy D; Fontana X; Koulibaly PM
    Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):355-65. PubMed ID: 25366711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
    Lizarraga KJ; Allen-Auerbach M; Czernin J; DeSalles AA; Yong WH; Phelps ME; Chen W
    J Nucl Med; 2014 Jan; 55(1):30-6. PubMed ID: 24167081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
    Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
    J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.